|
Monahan Lab
 Paul E. Monahan, MD
Associate
Professor, Department of Pediatrics,
Division of Hematology/Oncology
Attending Physician, Comprehensive Hemophilia Diagnostic and Treatment Center; University of North Carolina at Chapel Hill, N.C.
MD, University of Virginia School of Medicine
Laboratory phone: 919.843.4984
monoman@med.unc.edu
Publications:
- Kravtsov DK, Monahan PE, Gailani D. 2005. A classification system for cross-reactive material negative factor IV deficiency. Blood, prepublished online February 22, 2005.
- Schrijver I, Hong DW, Mandle L, Jones CD, DiMichele D, Monahan PE, Zehnder JL. 2005. High frequency of premature termination mutations in the factor V gene: Three factor V deficiency case reports and a mutation review. Thrombosis and Haemostasis, 93(3):610-1.
- Monahan PE, Aledort LM, for the ad hoc Hemophilia Inhibitor Study Group. 2004. Factors affecting choice of treatment agent for patients with hemophilia and inhibitor antibodies. American Journal of Hematology, 77:346-350.
- Van Cott KE, Monahan PE, Nichols T, Velander WH. 2004. Hemophilic factors produced by transgenic livestock: Abundance that can enable alternative therapies. Haemophilia, 10(s4):70-76.
- Jin D-Y, Zhang T-P, Gui T, Stafford DW, Monahan PE. 2004. Creation of a mouse expressing defective human factor IX. Blood, 104(6):1733-1739.
- Douvas MG, Monahan PE. 2004. Life-threatening thrombosis complicating the management of hepatic hemorrhage: anticoagulant treatment in a newborn with hemophilia B. Journal of Pediatric Hematology/Oncology, 26(4):258-263.
- McCarty DM, Fu H, Monahan PE, Toulson CE, Samulski RJ. 2003. Adeno-associated virus terminal repeat (TR) mutant generates double-strand vectors to overcome rate-limiting step in transduction in vivo. Gene Therapy, 10:2112-2118.
- Richardson MW, Allen GA, Monahan PE. 2002. Thrombosis in children: Current perspective and distinct challenges. Thrombosis and Haemostasis, 88(6):900-911.
- Monahan PE, White GC 2nd. 2002. Hemophilia gene therapy: update. Current Opinion in Hematology, 9(5):430-436.
- Monahan PE, Jooss K, Sands MS. 2002. Safety of adeno-associated virus gene therapy vectors: a current evaluation. Expert Opinions in Drug Safety, 1(1):79-92.
- Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D. 2001. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplantation, 28(4):405-407.
- Chao H, Monahan PE, Liu Y, Samulski RJ, Walsh CE. 2001. Sustained and complete phenotype correction of Hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Molecular Therapy, 4(3):217-222.
- McCarty DM, Monahan PE, Samulski RJ. 2001. Self-complementary adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Therapy, 8(16):1248-1253.
- Monahan PE, Samulski RJ. 2000. Adeno-associated virus vectors for gene therapy: More pros than cons? Molecular Medicine Today, 6(11):433-440.
- Malik AK, Monahan PE, Allen DL, Chen Bing-Guan, Samulski RJ, Kurachi K. 2000. Kinetics of recombinant adeno-associated virus (AAV)-mediated gene transfer. Journal of Virology, 74(8):3555-3565.
- Monahan PE, Samulski RJ. 2000. AAV vectors: Is clinical success on the horizon? Gene Therapy, 7(1):24-30.
- Chao HJ, Samulski RJ, Bellinger D, Monahan PE, Nichols T, Walsh CE. 1999. Persistent expression of canine factor IX in hemophilia B canines. Gene Therapy, 6(10):1695-1704.
- Monahan PE, Samulski RJ, Tazelaar J, Xiao X, Nichols TC, Bellinger DA, Read MS, Walsh CE. 1998. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Therapy, 5(1):40-49.
Personnel
|
